Follow The Filings

Avidity Partners Management LP David Witzke

Dallas, TX 21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $624M
  • 45 holdings
  • 2026 Q2
  • +41.2% QoQ
  • Top 5 70.9%

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 45 holdings

Top 5 70.9%, top 10 81.9%

  1. DNTH, Dianthus Therapeutics 32.8%
  2. CGON, CG Oncology 15.9%
  3. ORKA, Oruka Therapeutics 11.6%
  4. JBIO, Jade Biosciences 6.1%
  5. ELVN, Enliven Therapeutics 4.5%
  6. CATX, Perspective Therapeutics 3.4%
  7. AKTS, Aktis Oncology 2.5%
  8. PVLA 1.7%
  9. MOBI, Mobia Medical 1.7%
  10. RGEN, Repligen 1.7%
  11. Immunic 1.6%
  12. Senseonics 1.5%
  13. Other 15.0%

AUM over time

2026 Q2 $624M +41.2% QoQ
2021 Q3: $4.5B 2021 Q3: $4.5B
Q3 2021
2021 Q4: $4.7B, +4.5% QoQ 2021 Q4: $4.7B, +4.5% QoQ
Q4
2022 Q1: $4.8B, +1.9% QoQ 2022 Q1: $4.8B, +1.9% QoQ
Q1 2022
2022 Q2: $4.4B, −9.3% QoQ 2022 Q2: $4.4B, −9.3% QoQ
Q2
2022 Q3: $4.9B, +12.9% QoQ 2022 Q3: $4.9B, +12.9% QoQ
Q3
2022 Q4: $4.6B, −6.2% QoQ 2022 Q4: $4.6B, −6.2% QoQ
Q4
2023 Q1: $3B, −34.7% QoQ 2023 Q1: $3B, −34.7% QoQ
Q1 2023
2023 Q2: $2.9B, −5.0% QoQ 2023 Q2: $2.9B, −5.0% QoQ
Q2
2023 Q3: $2.5B, −13.3% QoQ 2023 Q3: $2.5B, −13.3% QoQ
Q3
2023 Q4: $2.7B, +10.5% QoQ 2023 Q4: $2.7B, +10.5% QoQ
Q4
2024 Q1: $3.1B, +13.0% QoQ 2024 Q1: $3.1B, +13.0% QoQ
Q1 2024
2024 Q2: $2.4B, −24.1% QoQ 2024 Q2: $2.4B, −24.1% QoQ
Q2
2024 Q3: $2B, −16.7% QoQ 2024 Q3: $2B, −16.7% QoQ
Q3
2024 Q4: $1B, −48.1% QoQ 2024 Q4: $1B, −48.1% QoQ
Q4
2025 Q1: $525M, −48.4% QoQ 2025 Q1: $525M, −48.4% QoQ
Q1 2025
2025 Q2: $502M, −4.4% QoQ 2025 Q2: $502M, −4.4% QoQ
Q2
2025 Q3: $439M, −12.5% QoQ 2025 Q3: $439M, −12.5% QoQ
Q3
2025 Q4: $347M, −21.0% QoQ 2025 Q4: $347M, −21.0% QoQ
Q4
2026 Q1: $442M, +27.4% QoQ 2026 Q1: $442M, +27.4% QoQ
Q1 2026
2026 Q2: $624M, +41.2% QoQ 2026 Q2: $624M, +41.2% QoQ
Q2

Book

2024 Q1 2023 Q4, filed 15 May, long equity only

Download CSV Download Excel All activity
Fusion Pharmaceuticals 4.47% Hold 6,500,328 $21.32 $139M — —
BSX, Boston Scientific 4.32%, was 3.98% Add +3.5% 1,956,000 $68.49 $134M +66,000 +$25M
ARVN, Arvinas 3.97% Add 0.0% 2,985,190 $41.28 $123M +73 +$361K
ISRG, Intuitive Surgical 2.91%, was 1.05% Add +165.9% 226,000 $399.09 $90M +141,000 +$62M
DNTH, Dianthus Therapeutics 2.63%, was 0.46% Add +123.2% 2,717,554 $30.00 $82M +1,500,000 +$69M
ACHC 2.57%, was 3.28% Reduce −13.1% 1,005,000 $79.22 $80M −151,692 −$10M
NBIX, Neurocrine Biosciences 2.39%, was 3.16% Reduce −18.5% 536,500 $137.92 $74M −121,500 −$13M
NTRA, Natera 2.37%, was 2.53% Reduce −27.6% 803,300 $91.46 $73M −306,700 +$3.9M
JAZZ, Jazz Pharmaceuticals 2.27%, was 2.19% Add +19.4% 584,000 $120.42 $70M +94,881 +$10M
AVTR, Avantor 2.22%, was 1.77% Add +27.0% 2,695,000 $25.57 $69M +573,156 +$20M
CI, Cigna 2.16% New 184,500 $363.19 $67M +184,500 +$67M
MRK, Merck 2.14% New 502,000 $131.95 $66M +502,000 +$66M
REGN, Regeneron 2.11% Hold 68,000 $962.49 $65M — —
CGON, CG Oncology 2.06% New 1,454,765 $43.90 $64M +1,454,765 +$64M
ILMN, Illumina 2.05% New 464,100 $137.32 $64M +464,100 +$64M
THC, Tenet Healthcare 2.04%, was 2.40% Reduce −31.0% 601,000 $105.11 $63M −270,000 −$2.7M
ALGN, Align Technology 2.00%, was 1.56% Add +21.3% 189,000 $327.92 $62M +33,200 +$19M
SNDX, Syndax Pharmaceuticals 1.85%, was 3.11% Reduce −38.9% 2,412,500 $23.80 $57M −1,537,500 −$28M
LLY, Eli Lilly 1.76%, was 1.81% Reduce −17.6% 70,000 $777.96 $54M −15,000 +$4.9M
UTHR, United Therapeutics 1.61%, was 1.90% Reduce −8.5% 217,000 $229.72 $50M −20,202 −$2.3M
Alpine Immune Sciences 1.50% New 1,174,700 $39.64 $47M +1,174,700 +$47M
RARE 1.41% Add +10.5% 933,500 $46.69 $44M +89,000 +$3.2M
CVS, CVS Health 1.40%, was 2.13% Reduce −26.4% 545,000 $79.76 $43M −195,000 −$15M
SGRY, Surgery Partners 1.39%, was 1.36% Add +23.9% 1,445,000 $29.83 $43M +279,068 +$5.8M
Intra-Cellular Therapies 1.34%, was 1.85% Reduce −15.5% 600,000 $69.20 $42M −110,000 −$9.3M
ABBV, AbbVie 1.33%, was 1.61% Reduce −20.2% 227,000 $182.10 $41M −57,405 −$2.7M
Blueprint Medicines 1.30%, was 2.07% Reduce −30.7% 426,000 $94.86 $40M −189,000 −$16M
Legend Biotech 1.21%, was 1.50% Reduce −2.4% 668,300 $56.09 $37M −16,700 −$3.7M
GPCR, Structure Therapeutics 1.19%, was 1.60% Reduce −20.0% 864,000 $42.86 $37M −216,000 −$7M
ALNY, Alnylam Pharmaceuticals 1.17% New 243,000 $149.45 $36M +243,000 +$36M
DHR, Danaher 1.16%, was 2.44% Reduce −50.4% 143,800 $249.72 $36M −146,200 −$31M
IDYA, Ideaya Biosciences 1.13%, was 1.97% Reduce −47.4% 799,700 $43.88 $35M −720,300 −$19M
AXSM, Axsome Therapeutics 1.11%, was 1.33% Reduce −6.2% 431,000 $79.80 $34M −28,400 −$2.2M
XENE, Xenon Pharmaceuticals 0.99%, was 1.37% Reduce −13.0% 710,000 $43.05 $31M −105,993 −$7M
LNTH, Lantheus 0.96%, was 0.86% Add +26.3% 480,000 $62.24 $30M +100,000 +$6.3M
CRBU, Caribou Biosciences 0.96%, was 1.33% Reduce −9.0% 5,785,352 $5.14 $30M −574,860 −$6.7M
MIRM, Mirum Pharmaceuticals 0.93% Hold 1,142,850 $25.12 $29M — —
RCKT, Rocket Pharmaceuticals 0.89%, was 1.88% Reduce −40.4% 1,025,000 $26.94 $28M −694,103 −$24M
Regenxbio 0.88% New 1,300,064 $21.07 $27M +1,300,064 +$27M
APGE, Apogee Therapeutics 0.82% New 384,893 $66.45 $26M +384,893 +$26M
NMRA, Neumora Therapeutics 0.80%, was 1.24% Reduce −9.6% 1,800,000 $13.75 $25M −190,632 −$9.2M
DXCM, DexCom 0.79% New 176,900 $138.70 $25M +176,900 +$25M
NGNE, Neurogene 0.76% Reduce −0.2% 465,237 $50.90 $24M −1,006 +$15M
Jasper Therapeutics 0.72% New 760,000 $29.36 $22M +760,000 +$22M
Immunome 0.70% Reduce −34.5% 873,891 $24.68 $22M −459,588 +$7.3M
TMO, Thermo Fisher Scientific 0.69%, was 3.53% Reduce −80.0% 36,600 $581.21 $21M −146,000 −$76M
GKOS, Glaukos 0.68% New 224,000 $94.29 $21M +224,000 +$21M
RVMD, Revolution Medicines 0.66%, was 0.06% Add +958.3% 635,000 $32.23 $20M +575,000 +$19M
PCVX, Vaxcyte 0.63%, was 1.30% Reduce −50.2% 284,000 $68.31 $19M −286,137 −$16M
Immunocore 0.60%, was 0.75% Reduce −4.6% 286,400 $65.00 $19M −13,800 −$1.9M

Showing top 50 of 85 by value

Exits / last held

Gone since 2023 Q4, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
Karuna Therapeutics 2.38% Exit 0 $316.51 $65M −206,000 −$65M
Immunogen 1.98% Exit 0 $29.65 $54M −1,829,215 −$54M
ZTS, Zoetis 1.73% Exit 0 $197.37 $47M −240,000 −$47M
HUM, Humana 1.67% Exit 0 $457.81 $46M −100,000 −$46M
BDX, Becton Dickinson 1.47% Exit 0 $243.83 $40M −165,706 −$40M
UNH, UnitedHealth Group 1.12% Exit 0 $526.46 $31M −58,500 −$31M
ARWR, Arrowhead Pharmaceuticals 0.80% Exit 0 $30.60 $22M −714,000 −$22M
CRNX 0.69% Exit 0 $35.58 $19M −529,000 −$19M
Holding 0.57% Exit 0 $19.88 $16M −780,900 −$16M
A, Agilent Technologies 0.50% Exit 0 $139.03 $14M −99,000 −$14M
INTC, Intellia Therapeutics 0.50% Exit 0 $30.49 $14M −447,434 −$14M
ARGX, Argenx 0.43% Exit 0 $380.42 $12M −31,000 −$12M
Holding 0.43% Exit 0 $42.40 $12M −276,888 −$12M
TVTX, Travere Therapeutics 0.27% Exit 0 $8.99 $7.4M −827,010 −$7.4M
Akero Therapeutics 0.20% Exit 0 $23.35 $5.5M −235,000 −$5.5M
CMPX, Compass Therapeutics 0.09% Exit 0 $1.56 $2.5M −1,599,600 −$2.5M
AMLX, Amylyx Pharmaceuticals 0.03% Exit 0 $14.71 $949K −64,501 −$949K
Caremax 0.01% Exit 0 $0.4984 $317K −636,000 −$317K

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2023 Q4. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 45 $624M +41.2% 13F-HR 8/14/2026 000179182726000005
2026 Q1 45 $494M — new holds 5/28/2026 000179182726000004
2026 Q1 46 $442M +27.4% 13F-HR 5/13/2026 000179182726000003
2025 Q4 39 $347M −21.0% 13F-HR 2/13/2026 000179182726000002
2025 Q3 43 $439M −12.5% 13F-HR 11/14/2025 000179182725000008
2025 Q2 56 $502M −4.4% 13F-HR 8/14/2025 000179182725000007
2025 Q1 67 $525M −48.4% 13F-HR 5/15/2025 000179182725000005
2024 Q4 63 $1B −48.1% 13F-HR 2/14/2025 000179182725000002
2024 Q3 81 $2B −16.7% 13F-HR 11/14/2024 000179182724000011
2024 Q2 85 $2.4B −24.1% 13F-HR 8/14/2024 000179182724000007
2024 Q1 90 $3.1B +13.0% 13F-HR 5/15/2024 000179182724000004
2023 Q4 74 $2.7B +10.5% 13F-HR 2/14/2024 000179182724000002
2023 Q3 83 $2.5B −13.3% 13F-HR 11/14/2023 000179182723000006
2023 Q2 93 $2.9B −5.0% 13F-HR 8/14/2023 000179182723000004
2023 Q1 83 $3B −34.7% 13F-HR 5/15/2023 000179182723000003
2022 Q4 85 $4.6B −6.2% 13F-HR 2/14/2023 000179182723000002
2022 Q3 97 $4.9B +12.9% 13F-HR 11/14/2022 000179182722000008
2022 Q2 82 $4.4B −9.3% 13F-HR 8/15/2022 000179182722000006
2022 Q1 92 $4.8B +1.9% 13F-HR 5/16/2022 000179182722000004
2021 Q4 97 $4.7B +4.5% 13F-HR 2/14/2022 000179182722000002
2021 Q3 105 $4.5B — 13F-HR 11/15/2021 000179182721000006

About

Avidity Partners Management LP

21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
Avidity Partners Management LP
Notable person
David Witzke
Location
Dallas, TX
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf